

Stephanie David

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1630605/publications.pdf>

Version: 2024-02-01

19
papers

425
citations

687363

13
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

822
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-viral nanosystems for systemic siRNA delivery. <i>Pharmacological Research</i> , 2010, 62, 100-114.	7.1	100
2	Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 131, 99-108.	4.3	41
3	Nature as a source of inspiration for cationic lipid synthesis. <i>Genetica</i> , 2010, 138, 153-168.	1.1	30
4	siRNA LNCs “ A novel platform of lipid nanocapsules for systemic siRNA administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 448-452.	4.3	30
5	In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. <i>International Journal of Pharmaceutics</i> , 2012, 423, 108-115.	5.2	28
6	Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118572.	5.2	21
7	EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. <i>International Journal of Pharmaceutics</i> , 2013, 454, 748-755.	5.2	20
8	DNA Nanocarriers for Systemic Administration: Characterization and In Vivo Bioimaging in Healthy Mice. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e64.	5.1	20
9	gH625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line. <i>Biomacromolecules</i> , 2019, 20, 3076-3086.	5.4	20
10	Versatile electrostatically assembled polymeric siRNA nanovectors: Can they overcome the limits of siRNA tumor delivery?. <i>International Journal of Pharmaceutics</i> , 2019, 567, 118432.	5.2	19
11	Stealth magnetic nanocarriers of siRNA as platform for breast cancer theranostics. <i>International Journal of Pharmaceutics</i> , 2017, 532, 660-668.	5.2	18
12	siRNA delivery system based on magnetic nanovectors: Characterization and stability evaluation. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 106, 287-293.	4.0	16
13	Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. <i>Journal of Gene Medicine</i> , 2012, 14, 769-775.	2.8	13
14	Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 157, 74-84.	4.3	13
15	Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and in vivo biodistribution improvements. <i>RSC Advances</i> , 2019, 9, 27264-27278.	3.6	11
16	Use of experimental design methodology for the development of new magnetic siRNA nanovectors (MSN). <i>International Journal of Pharmaceutics</i> , 2013, 454, 660-667.	5.2	10
17	Homogeneous distribution of fatty ester-based active cosmetic ingredients in hydrophilic thin films by means of nanodispersion. <i>International Journal of Cosmetic Science</i> , 2020, 42, 512-519.	2.6	8
18	Modelling the response surface to predict the hydrodynamic diameters of theranostic magnetic siRNA nanovectors. <i>International Journal of Pharmaceutics</i> , 2015, 478, 409-415.	5.2	7

#	ARTICLE	IF	CITATIONS
19	Fluorescence Microscopy as a Tool for Nanomedicine-Cell Interactions Study: Input of Particle Design and of Analytical Strategy. <i>Microscopy and Microanalysis</i> , 2018, 24, 1316-1317.	0.4	0